3 Dividend Kings That Earn Their Crown Every Quarter
The article highlights Dividend Kings, focusing on PepsiCo and Becton Dickinson. It says PepsiCo has raised its dividend for 54 straight years, with a ~3.9% yield and a recent ~4% increase, and notes organic revenue growth of 1%–3% per quarter. For Becton Dickinson, it cites 53 years of dividend growth, a ~2.8% yield, and fiscal 2026 guidance of EPS $14.75–$15.05 (midpoint) and low single-digit revenue growth.
Primarily a long-term income/durability narrative; no new PepsiCo-specific catalyst beyond dividend framing.
Article frames PepsiCo’s dividend durability and pricing power, and notes a recent ~4% dividend increase and ~3.9% yield.
Low near-term impact; any reaction would be sentiment/positioning rather than fundamentals.
Background
The piece is a “Dividend Kings” style roundup describing PepsiCo and Becton Dickinson’s long dividend histories and business resilience.
Why it matters
Because it lacks a clearly new, date-specific corporate event (e.g., fresh earnings release, contract award, or updated guidance), it’s more useful for positioning/long-horizon screening than for short-term trading decisions.
Market relevance
Supports a defensive income bias in staples and medical devices, but provides no clear new catalyst for immediate repricing.
Market effects
Reinforces the “dividend durability” trade in consumer staples and medical devices; may marginally support relative strength for defensive names.
No specific regional linkage beyond broad US-listed defensive demand.
No direct global macro or cross-border event described.
Alternative perspectives
Dividend-focused narratives can mask valuation risk or slower organic growth; “durability” may already be priced in.
The article doesn’t address near-term margin pressures, competitive dynamics, or whether the cited guidance is newly updated versus stale.
Key entities
- companyPepsiCo
Dividend-growth and pricing-power narrative; cites ~3.9% yield and a recent ~4% dividend increase.
- companyBecton, Dickinson and Co.
Healthcare device/diagnostics defensive profile; cites fiscal 2026 low single-digit revenue growth and EPS $14.75–$15.05.


